Mazzariello Gina 4

What Happened
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals (AMLX), received two equity awards on March 5, 2026: 74,660 restricted stock units (RSUs) and 111,990 derivative share awards, for a total of 186,650 award shares. Both grants were reported at $0.00 (no cash paid at grant). These were awards/derivative grants (not open-market purchases or sales) and therefore represent compensation, not a liquidity event.

Key Details

• Transaction date: 2026-03-05; Form 4 filed 2026-03-09 (filed within the standard 2-business-day window).
• Award amounts and reported price: 74,660 RSUs @ $0.00; 111,990 derivative shares @ $0.00 (total 186,650).
• Vesting (per filing footnotes):
  • RSUs (74,660): vest in 4 equal annual installments, first vesting on March 1, 2027, subject to continued service.
  • Derivative award/option (111,990): 25% vests/exercisable on March 1, 2027; remaining vests monthly over the next 36 months, subject to continued service.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No sales or exercises reported — these are grants (compensation), not dispositions.

Context

• These grants are typical equity compensation for executives; they generally vest over time and are intended to align incentives, not indicate immediate trading intent.
• The derivative award appears to be an option-style grant with standard 4-year-style vesting (25% after one year, then monthly), meaning the award becomes exercisable over time rather than immediately marketable.
• Because this is a grant (and not a purchase or sale), it is less directly informative about the insider’s near-term view of the stock price than an open-market buy or sell.